CollPlant Biotechnologies (CLGN) received a Nasdaq notice on March 24, 2026 that its ordinary shares had closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The written notice was issued by Nasdaq on March 23, 2026 and announced the following day.
Nasdaq granted the company a 180‑day compliance window that ends on September 21, 2026. To regain compliance, the bid price must reach or exceed $1.00 for at least 10 consecutive business days within that period. If the company fails to meet the requirement, Nasdaq may allow a second 180‑day period contingent on other listing standards, and the company may consider a reverse split to restore compliance.
The notice comes amid a steep decline in CollPlant’s share price. The stock’s 52‑week high was $4.98 and its 52‑week low $0.495. On March 24, the share traded at $0.71, a level roughly one‑fifth of its 52‑week high and far below the price it reached a year earlier. The sustained low price reflects weak financial performance, large ongoing losses, heavy cash burn, and a shrinking equity base, according to analysts.
Management has stated it will monitor the bid price and evaluate options to cure the deficiency, including a potential reverse split. Analysts have given the company a “Sell” rating with a $2.00 price target, while others maintain higher targets, indicating uncertainty about the company’s ability to recover.
The market responded positively to the notice, reflecting the reprieve offered by the 180‑day compliance window. However, the underlying business fundamentals remain weak, and investors remain cautious about the company’s long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.